Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
BridgeBio Pharma, Inc. (BBIO) had Receiveable Turnover of 5.31 for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$9.30M |
|
$-643.20M |
|
$2.45M |
|
$6.86M |
|
$616.67M |
|
$-607.37M |
|
$-45.88M |
|
$-653.25M |
|
$-653.25M |
|
$-653.25M |
|
$-653.25M |
|
$-653.25M |
|
$-653.25M |
|
$-607.37M |
|
$-600.88M |
|
162.79M |
|
162.79M |
|
$-3.95 |
|
$-3.95 |
|
| Balance Sheet Financials | |
$477.59M |
|
$11.82M |
|
$68.79M |
|
$546.38M |
|
$143.84M |
|
$1.73B |
|
$1.75B |
|
$1.89B |
|
$-1.34B |
|
$-1.37B |
|
$-1.34B |
|
175.08M |
|
| Cash Flow Statement Financials | |
$-527.72M |
|
$54.03M |
|
$451.54M |
|
$416.88M |
|
$394.73M |
|
$-22.15M |
|
$108.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.32 |
|
-- |
|
-- |
|
4.50 |
|
-1.29 |
|
73.71% |
|
-6528.75% |
|
-6528.75% |
|
-6458.95% |
|
-7021.94% |
|
-6913.92% |
|
$-529.03M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
|
Receiveable Turnover |
5.31 |
68.70 |
|
48.64% |
|
47.71% |
|
-119.56% |
|
-170.24% |
|
$-7.67 |
|
$-3.25 |
|
$-3.24 |
|